OTI-010 Osiris Therapeutics/JCR Pharmaceuticals

Current Opinion in Investigational Drugs

Volumn 7, Issue 5, 2006, Pages 473-481

  Taupin, Philippe ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

'ALLOGEN'; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIINFLAMMATORY AGENT; CISPLATIN; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; DENILEUKIN DIFTITOX; DOXORUBICIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; JR 031; METHOTREXATE; METHYLPREDNISOLONE; ORPHAN DRUG; OTI 010; PENTOSTATIN; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER PATIENT; CELL DIFFERENTIATION; CELL POPULATION; CELL SURVIVAL; CLINICAL TRIAL; CROHN DISEASE; DIARRHEA; DISEASE SEVERITY; DONOR; DRUG SYNTHESIS; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEARTBURN; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; INFECTION; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; RAT; UNSPECIFIED SIDE EFFECT; VOMITING;

ADOLESCENT; ADULT; ANIMALS; BONE MARROW TRANSPLANTATION; CELL CULTURE TECHNIQUES; CLINICAL TRIALS; CROHN DISEASE; GRAFT VS HOST DISEASE; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; ORPHAN DRUG PRODUCTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 33646846847     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. 327297 Osiris Therapeutics initiates clinical trial using donor-derived adult stem cells Osiris Therapeutics Inc PRESS RELEASE 1999 June 08
2. 327352 Cell therapy program Osiris Therapeutics Inc COMPANY WORLD WIDE WEB SITE 1999 June 09
3. 350813 Phenotype of human mesenchymal stem cells isolated directly from bone marrow Davis-Sproul J, McNeil R, Simonetti D, Craig S, Moseley A, Deans R, Moorman M BLOOD 1999 94 10 Suppl 1 Abs 3905
4. 386589 Research and clinical development programs Osiris Therapeutics Inc COMPANY WORLD WIDE WEB SITE 2000 October 23
5. 394517 Multilineage potential of adult human mesenchymal stem cells Pittenger MF, Mackay AM, Beck SC, Jaiswal RK. Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR SCIENCE 1999 284 5411 143-147
6. 433228 Effects of chemotherapeutic agents on the proliferation differentiation, and stromal support capacity of human mesenchymal stem cells Archambault MP, Howard L, Butterfield AM, Peter SJ BLOOD 2001 98 11 Suppl 2 Abs 4235
7. 495015. BIO 2003 - International Biotechnology Conventin and Exhibition (Part VII), Washington, DC, USA, 21-25 June, 2003 Aird J IDDB MEETING REPORT 2003 June 21-25.
8. 502952 Osiris licenses stem cell technology to JCR Pharmaceuticals. Osiris Therapeutics Inc PRESS RELEASE 2003 August 28
9. 570810 Stem cells and regenerative medicine - SRI's Fourth Annual Meeting: Commercial Implications for the pharmaceutical and biotech Industries, Princeton, NJ, USA, 18-19 October 2004 IDdb author IDDB MEETING REPORT 2004 October 18-19
10. 582522 FDA grants Fast Track status to Osiris's GvHD stem cell therapy Osiris Therapeutics Inc PRESS RELEASE 2005 January 31
11. 616286 Osiris and JCR Pharmaceuticals reach milestone, expand license agreement Companies to expand stem cell technology into a new market opportunity Osiris Therapelitics Inc PRESS RELEASE 2005 August 04
12. 628422 New stem cell treatment being evaluated for critically III bone marrow transplant patients; osiris launches a phase II clinical trial for severe graft vs host disease Osiris Therapeutics Inc PRESS RELEASE 2005 October 12
13. 632720 Osiris's heart attack stem cell therapy safe in phase 1 Osiris Therapeutics Inc PRESS RELEASE 2005 November 04
14. 630569 Osiris starts phase II stem cell trial in Crohn's disaase Osiris Therapeutics Inc PRESS RELEASE 2005 December 08
15. 642237 Osiris's stem cells get US Orphan status for GvHD Osiris Therapeutics Inc PRESS RELEASE 2005 Decamber 20
16. 643688 The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105) Barry FP, Boynton RE, Haynesworth S, Murphy JM, Zaia J BIOCHEM BIOPHYS RES COMMUN 1999 265 1 134-139
17. 643694 Human mesenchymal stem cells modulate allogeneic immune cell responses Aggawal S, Pittenger MF BLOOD 2005 105 4 1815-1822
18. 643702 The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells Barry F, Boynton R, Murphy M, Zaia J BIOCHEM BIOPHYS RES COMMUN 2001 289 2 519-624
19. 643706 Human marrow-derived mesenchymal stem cells (MSCs) express hematopoletic cytokines and support long-term hematopolesis when differentiated toward stromal and osteogenic lineages Majumdar MK, thiede MA, Haynesworth SE, Bruder SP, Gerson SL J HEMATOTHER STEM CELL RES 2000 9 6 841-648
20. 643707 Mesenchymal stem cells as vehicles for gene delivery Mosca JD, Hendricks JK, Buyaner D, Davis-Sproul J, Chuang LC, Majumdar MK, Chopra R, Barry F, Murphy M, Thiede M A, Junker U, Rigg RJ, Forestell SP, Bohnlein E, Storb R, Sandmaier BM CLIN ORTHOP 2000 379 Suppl S71-S90
21. 643859 Intra-portal infusion of adult mesenchymal stem cells enhances survival of allogeneic beta cells In Immunocompetent rate Archambault MP, Campbell SE, Vanguri P, Mcintosh KR BLOOD 2002 100 11 Abs 2404
22. 656535 Cytolytic pathways in haematopoletic stem-cell transplantation van den Brink MR, Burakoff SJ NAT REV IMMUNOL 2002 2 4 273-281
23. 656537 Allogeneic hematopoletic cell trensplantatlon as consolidation immunotherapy of cancer after autologous transplantation Maris MB, Storb R ACTA HAEMATOL 2005 114 4 221-229
24. 656539 Mesenchymal stem cells Caplan AI J ORTHOP RES 1991 9 5 641-650
25. 656543 Characterization of cells wtth osteogenic potential from human marrow Haynesworth SE, Goshima J, Goldberg VM, Caplan AI BONE 1992 13 1 81-88
26. 656546 HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O EXP HEMATOL 2003 31 10 890-896
27. 656548 Characterization and functionality of call surface molecules on human mesenchymal stem cells Majumdar MK, Keane-Moore M, Buyaner D, Hardy WB, Moorman MA, McIntosh KR, Mosca JD J BIOMED SCI 2003 10 2 228-241
28. 656550 Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S. Ucker D, Deans R, Moseley A, Hoffman R EXP HEMATOL 2002 30 1 42-48
29. 656553 Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O SCAND J IMMUNOL 2003 57 1 11-20
30. 656696 Characterization of MSC potential to treat GVHD using molecular markers linked to MSC-mediated immunosuppresslon in vitro Carter D, Tyrell A, Bubnic S, Marcelino M, Kedzierski K, Monroy R, Mills R, Danilkovitch A BLOOD 2005 106 11
31. 656687 Modulation of immune cell responses by human mesenchymal stem cells Aggarwal S, Pittenger MF BLOOD 2004104 11 Abs 1288
32. 656698 Evidence for selective suppression of alloreactivity by mesenchymal stem cells Beggs KJ, Kavalkovitoh KW, Bomeman JN, Murphy MJ, Bany PP. Stewart MG, Proctor RL, McIntosh KR BLOOD 2001 98 11 Abs 2719
33. 656701 Mode of delivery of human mesenchymal stem cells affects engraftment of human CD34+ cells in NOD/SCID mice Liu L, Mbalaviele G, Lee K, Mosca J, Deans R BLOOD 2000 96 11 Abs 3309
34. 656702 Allogeneic rat mesenchymal stem cells do not elicit an immune response after implantation in immunocompetent recipients Archambault MP, McIntosh KR, Duty A, Peter SJ BLOOD 2000 96 11 Abs 3295
35. 656703 Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL J CELL PHYSIOL 1998 176 1 57-66
36. 658214 Mesenchymal stem cells can be differentiated Into endothelial cells in vitro Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, Warner C STEM CELLS 2004 22 3 377-384
37. 658608 Hematopoletic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, Gerson SL, Lazarus HM, Cairo M, Stevens CE, Rubinstein P, Kurtzberg J N ENGL J MED 2001 344 24 1815-1822
38. 658612 Unrelated donor hematopoletic cell transplantation: Marrow or umbilical cord blood? Grewal SS. Barker JN, Davies SM, Wagner JE BLOOD 2003 101 11 4233-244
39. 658625 Mesenchymal stem cells avoid allogeneic rejection Ryan JM, Barry FP, Murphy JM, Mahon BP J INFLAMM 2005 2 8
40. 658631 Isolation of multipotent mesenchymal stem cells from umbilical cord blood Lee OK, Kuo TK, Chen MM, Lee KD, Hsieh SL, Chen TH BLOOD 2004 103 5 1669-1675
41. 658632 Mesenchymal stem cells: Isolation, in vitro expansion and characterization Beyer NN, da Silva ML HANDB EXP PHARMACOL 2006 174 249-282
42. 658640 Mesenchymal stem cells: Isolation and therapeutics Alhadlaq A, Mao JJ STEM CELLS DEV 2004 13 4 438-448
43. 658988 IBMTR Severity index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, Cahn JY, Calderwood S, Gratwohl A, Socie G, Abecasis MM, Sobocinski KA, Zhang MJ, Horowitz MM BR J HAEMATOL 1997 97 4 855-864
44. 658995 Mesenchymal stem cells and their potential as cardiac therapeutics Pittenger MF. Martin BJ CIRC RES 2004 96 1 9-20.
45. 659005 Immunobiology of human mesenchymal stem cells and future use In hematopoletic stem cell transplantation Le Blanc K, Ringden O BIOL BLOOD MARROW TRANSPLANT 2005 11 5 321-334
46. 659018 Treatment of severe acute graft-versus-host disease with third party haploidentIcal mesenchymal stem calls Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O LANCET 2004 363 9419 1439-1441
47. 659019 Cotramplantatlon of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A BIOL BLOOD MARROW TRANSPLANT 2005 11 5 389-398
48. 059032 Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms Rasmusson I, Ringden O, Sundberg B, Le Blanc K EXP CELL RES 2005 305 1 33-41
49. 659326 Bone marrow transplantation for sickle cell anemia: Progress and prospects Iannone R, Ohene-Frempong K, Fuchs EJ, Casella JF, Chen AR PEDIATR BLOOD CANCER 2005 44 5 438-440
50. 659330 Marrow transplantation from related donors other than HLA-identical siblings Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, Sanders JE, Stewart P, Buckner CD, Storb R, et at N ENGL J MED 1986 313 13 765-771
51. 659361 The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors Morishima Y, Sasazuki T, Inoto H, Juji T, Akaza T, Yamamoto K, Ishikawa Y, Kato S, Sao H, Sakamaki H, Kawa K. Hamajima N, Asano S, Kodera Y, BLOOD 2002 99 11 4200-4206
52. 659372 Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation Weisdorf D, Hakke R, Blazar B. Miller W, McGlave P, Ramsay N. Kersey J, Filipovich A TRANSPLANTATION 1991 51 6 1197-1203
53. 659376 The role of minor histocompatibility antigens in GVHD and reiection: A mini-review Goulmy E, Voogt P, van Els C, de Bueger M, van Rood J BONE MARROW TRANSPLANT 1991 7 Suppl 1 49-51
54. 659385 Mismatches of minor histocompatiblitty antigens between HLA-identical donors and racipients and the development of graft-versus-host disease after bone marrow transplantation Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J, Gratwohl A, Vogelsang GB, van Houwelingen HC, van Rood JJ N ENGL J MED 1996 334 5 281-285
55. 659392 Acute graft-versus-host disease: Pathophystology, clinical manifestations, and management Couriel D, Caldera H, Champlin R, Komanduri K CANCER 2004 101 9 1936-1946
56. 659491 Chronic graft-vereus-host disease Horwitz ME, Sullivan KM BLOOD REV 2006 20 1 15-27
57. 659498 New strategies in the treatment of graft-versus-host disease Basara N, Blau IW, Willenbacher W, Kiehl MG, Fauser AA BONE MARROW TRANSPLANT 2000 25 Suppl 2 S12-S15
58. 659503 Novel pharmacotherapeutic approaches to prevention and treatment of GVHD Jacobsohn DA, Vogelsang GB DRUGS 2002 62 6 879-889
59. 659504 Novel strategies for sterold-refractory acute gaft-versus-host disease Bolanos-Meade J, Vogelsang GB CURR OPIN HEMATOL 2005 12 1 40-44
60. 659506 Pentostatin for the treatment of chronic graft-versus-host disease in children Goldberg JD, Jacobsohn DA, Margolis J, Chen AR, Anders V, Phelps M, Vogelsang GB J PEDIATR HEMATOL ONCOL 2003 25 7 584-588
61. 659532 Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Ho VT, Zahrieti D, Hochberg E, Micale E, Levin J, Reynolds C, Steckel S, Cutler C, Fisher DC, Lee SJ, Alyea EP, Ritz J, Soiffer RJ, Antin JH BLOOD 2004 104 4 1224-1226
62. 659743 Non-HLA immunogenetics in hematopoietic stem cell transplantation Dickinson AM, Charron D CURR OPIN IMMUNOL 2005 17 5 517-525
63. 659758 The biology of graft-versus-host reactions Billingham RE HARVEY LECTURES: DELIVERED UNDER AUSPICES HARVEY SOC NEW YORK 1966-1967 1966 62 21-78
64. 660656 Adult human mesenchymal stem cell as a target for neoplastic transformation Serakinci N, Guldberg P, Burns JS, Abdallah B, Schrodder H, Jensen T, Kassem M ONCOGENE 2004 23 29 5095-5098
65. 660857 Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, Seo BM, Sonoyama W, Zheng JJ, Baker CC, Chen W, Ried T, Shi S STEM CELLS 2005 10 [Epub ahead of print]
66. 660858 Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells Burns JS, Abdallah BM, Guldberg P, Rygaard J, Schroder HD, Kassem M CANCER RES 2005 15 65 8 3126-3135
67. 660859 Spontaneous human adult stem cell transformation Rubio D, Garcia-Cagtro J. Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bemnad A CANCER RES 2005 65 8 3035-3039
68. 660860 Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis Djouad F, Fritz V, Apparailly F, Louis-Plence P, Bony C, Sany J, Jorgensen C, Noel D ARTHRITIS RHEUM 2005 52 5 1595-1603
69. 662482 Acute graft-versus-host disease Bolanos-Meade J, Vogelsang GB CLIN ADV HEMATOL ONCOL 2004 2 10 672-82
70. 662457 Transfusion-associated graft-versus-host disease: A serious residual risk of blood transfusion Higgins MJ, Blackall DP CURR HEMATOL REP 2005 4 6 470-6
71. 662480 High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors McGuire WP CURR PROBL CANCER 1998 22 3 135-77